The Biggest GLP-1 Stories of 2026 So Far

Nine months into 2026, the GLP-1 market looks different than it did on New Year’s Day. Two obesity pills are on pharmacy shelves. Medicare pays for weight-loss medicine. Semaglutide is off patent in eight countries. And the company that invented it had one of the worst February trading days in its history.

Here is what happened, with dates, and what it means in practice. None of this is medical advice.

What changed first in 2026?

On January 5 Novo Nordisk launched the Wegovy pill, once-daily oral semaglutide 25 mg, at more than 70,000 US pharmacies [1]. Cash prices started at $149 a month for the 1.5 mg dose and topped out at $299 for the highest doses. Commercially insured patients could pay as little as $25 a month with the savings offer.

It worked. By early June the pill had passed three million prescriptions in a little over five months, roughly one filled every five seconds, which Novo called one of the strongest US pharmaceutical launches by volume on record [10]. Novo said more than 80% of new Wegovy pill prescriptions were for people new to GLP-1 therapy, which suggests the tablet is expanding the market rather than simply converting injection users [10]. The figure comes from the company’s own prescription data, not an independent audit.

For anyone who has avoided these drugs because of needles, that is the single most practical change of the year.

Why did Novo Nordisk’s stock crater in February?

Because the pill’s success did not fix the math. On February 3 Novo guided to an adjusted 2026 sales decline of 5% to 13% at constant exchange rates, against an average analyst expectation of roughly a 2% drop [2]. The figure is an adjusted one: it strips out a $4.2 billion reversal of 340B rebate provisions, without which the midpoint of the guidance would have been about -1% [16]. The company blamed “unprecedented” US pricing pressure from the most-favored-nation agreement signed the previous November, plus competition from Eli Lilly and patent expiries abroad.

Shares fell about 16% the next day, wiping close to $50 billion from the company’s value. Full-year 2025 sales had actually grown 10% at constant currencies to DKK 309 billion, so this was entirely about the year ahead. Novo announced buybacks of up to DKK 18.8 billion and kept going.

The stock touched a two-year low on March 3 and was down roughly 30% year to date by late March.

What is TrumpRx and does it save money?

TrumpRx.gov launched on February 6 [3]. It does not sell drugs. It is a referral site that routes patients to manufacturers’ own discount programs.

The listed prices were real, though. Ozempic went from a $1,028 monthly list price to an average of $350, injectable Wegovy from $1,349 to an average of $350 and as low as $199 depending on dose, and the Wegovy pill from a $1,349 list to as low as $149 [3]. By May the site showed Ozempic near $285 and Wegovy near $349.

Three weeks after the launch, Novo did something bigger. On February 24 it announced that from January 1, 2027 the list price of Wegovy injection and tablets, Ozempic injection and Rybelsus tablets would fall to $675 a month [4]. That is roughly a 50% cut for Wegovy and 35% for Ozempic. List prices matter most for people in high-deductible or coinsurance plans, whose share of cost is calculated from them.

Did the compounding fight finally end?

Close to it. February was chaotic. On the 5th, Hims & Hers launched a $49 compounded oral semaglutide, undercutting the $149 Wegovy pill. On the 6th the FDA said it would restrict the GLP-1 ingredients used in compounding, and the Department of Health and Human Services referred Hims to the Justice Department. On the 7th Hims pulled the product. On the 9th Novo sued Hims for patent infringement, and the company’s shares fell 29%.

Then, on March 3, the FDA released 30 warning letters to telehealth companies and online clinics over misleading claims about compounded GLP-1s. Six days later Novo and Hims announced a settlement and a partnership: Hims would sell branded Ozempic and Wegovy at standard self-pay prices and stop advertising compounded GLP-1s, except where a branded product cannot meet a specific patient’s documented clinical need [6].

In May the FDA proposed permanently excluding semaglutide, tirzepatide and liraglutide from the list of drugs that 503B outsourcing facilities can compound in bulk. The comment period closed on July 30, and no final rule has been published. Patient-specific compounding at 503A pharmacies remains legal, and compounded semaglutide still trades at roughly $178 to $299 a month, so the price gap has not gone away.

What did the FDA say about Novo Nordisk’s safety reporting?

On March 5 the agency sent Novo Nordisk’s US headquarters a warning letter citing serious violations of postmarketing adverse drug experience regulations [5]. It said Novo had failed to follow its own procedures for reporting adverse events and cited three deaths, one by suicide, in patients taking semaglutide that had not been submitted on time.

The FDA did not tie the deaths to the drug. But it wrote that the failure to identify root causes raised concerns about the company’s ability to monitor the safety of its products. It was Novo’s third FDA letter in six months, after one in September 2025 over the Oprah Winfrey promotional video and one in November over contract manufacturing.

Two obesity pills in three weeks: what happened in March and April?

On March 19 the FDA approved Wegovy HD, a 7.2 mg once-weekly semaglutide injection, just 54 days after filing [7]. It came through the Commissioner’s National Priority Voucher pilot, a new fast-track program, and was the fourth product cleared under it. In the STEP UP trial the dose produced 20.7% mean weight loss, with about one in three participants losing 25% or more. The label requires four weeks of tolerating 2.4 mg first, and gastrointestinal side effects were more common at the higher dose. The FDA also noted reports of altered skin sensation, described as sensitivity, pain or burning, which occurred more often at 7.2 mg than at lower doses and generally resolved on its own or with a dose reduction; the agency said it is investigating further [7].

Then on April 1 the FDA approved Eli Lilly’s Foundayo (orforglipron), the first small-molecule GLP-1 pill for weight management [8]. Because it is not a peptide, it survives digestion without special handling, so it can be taken at any time of day with or without food. Oral semaglutide, by contrast, still has to be taken on an empty stomach. Foundayo went on sale through LillyDirect on April 6, with some insured patients paying $25 a month and self-pay starting at $149.

Two rival obesity pills, three weeks apart, both under a fast-track program that did not exist two years ago.

What happened to semaglutide’s patents?

They started falling. Canada went first on January 4, then India on March 20, where more than five domestic manufacturers launched generics within days, several priced 70% to 90% below the originator [11]. China and Brazil followed, part of a first wave covering eight markets that also includes Mexico, Turkey, Saudi Arabia and South Africa.

Dr. Reddy’s launched semaglutide for diabetes in India at about 4,200 rupees a month. Bloomberg reported in August that the cheap copies had not displaced branded products as fast as expected, partly because of pen supply and prescribing habits.

None of this affects the United States, where exclusivity runs to roughly 2032. But it removes a chunk of Novo’s growth, and it is the reason the company keeps talking about CagriSema and amycretin.

When did Medicare start covering weight-loss drugs?

July 1, 2026. CMS announced the Medicare GLP-1 Bridge in May and launched it at the start of July [9]. Eligible Part D enrollees who meet the clinical criteria can get Wegovy injections and tablets, Foundayo tablets or the Zepbound KwikPen for a flat $50 monthly copay through December 31, 2027.

Read the fine print before you get excited. The Bridge operates outside the Part D benefit, so:

• The $50 does not count toward your deductible or the $2,100 annual out-of-pocket cap
• Extra Help and other low-income subsidies do not apply, so it is $50 for everyone
• The Medicare Prescription Payment Plan cannot be used for it
• Humana acts as the central claims processor
• Ozempic and Mounjaro are not on the covered list, because this is a weight-management program

A broader framework called the BALANCE model launched for Medicaid in May but was delayed indefinitely for Part D after pushback from insurers, which is why the Bridge became the main pathway.

What did the trial data show this year?

Mixed, and mostly bad for Novo.

On February 23, the open-label REDEFINE 4 trial showed CagriSema producing 23% weight loss at 84 weeks but failing to prove non-inferiority against tirzepatide 15 mg, which reached 23.6% [15]. Novo shares fell again. In August, REIMAGINE 4 in type 2 diabetes missed its dual primary endpoint on blood sugar against the same comparator.

On July 31 the ZEUS trial of ziltivekimab, an entirely different Novo drug, missed its primary endpoint, and the stock dropped about 9%.

Meanwhile Eli Lilly reported on May 21 that its triple hormone agonist retatrutide produced 28.3% average weight loss at 80 weeks on the 12 mg dose in the phase 3 TRIUMPH-1 trial, the largest late-stage obesity result recorded [12]. That figure describes participants who stayed on treatment; counting everyone randomized regardless of adherence, the average was 25.0%. Two more TRIUMPH trials succeeded in July. Retatrutide is still investigational and Lilly plans to file it in the first quarter of 2027.

Novo’s best data came last. On September 7 the STEP Young trial, in 165 children, reported that 40.4% of children aged 6 to under 12 with obesity were no longer classified as having obesity after 68 weeks on semaglutide, against none (0%) on placebo [14]. That 40.4% assumes full adherence to treatment. Both groups also received a reduced-calorie diet and more physical activity. Novo said safety was consistent with adult and adolescent trials, with no safety concerns identified for growth or pubertal development. Full data are due at ObesityWeek in November. The result landed three days after a study in Pediatrics reported that off-label GLP-1 prescribing to US children aged 8 to 11 with obesity rose from 0.03% in 2019 to 9.3% by June 2026, a more than 300-fold increase, even though no GLP-1 is approved under age 12 [17]. A label expansion would need its own FDA review.

Did anything go right for Novo in 2026?

Yes, and it is mostly the pill. On August 4 the company raised its full-year guidance, now expecting an adjusted sales change of -4% to -12% at constant exchange rates instead of -5% to -13%, crediting the Wegovy pill and the Wegovy HD launch.

Internationally, the pill kept collecting approvals. The MHRA cleared the Wegovy tablet on June 11, making the UK the first European country to license a GLP-1 weight-loss pill. The European Commission followed on July 15, approving both the pill and the 7.2 mg pen EU-wide [13]. That made the Wegovy pill’s fifth regulatory clearance, after the United States, the UK, the United Arab Emirates and Bahrain.

Eli Lilly countered in August, when the MHRA authorized orforglipron and the UK became the first European market for that tablet too.

What should you actually do with this information?

If you are on a GLP-1 or considering one, three practical points come out of 2026 so far:

1. There are now oral options approved for weight management, and they cost far less in cash than injections. Whether a pill suits you is a clinical question for your provider, not a price question.
2. If you are on Medicare, the GLP-1 Bridge is a real pathway but a narrow one, with specific covered drugs and criteria. Ask your prescriber to check eligibility rather than assuming.
3. Prices are still moving. List prices drop again on January 1, 2027, and the Medicare negotiated price takes effect the same day, headlined at about $274 a month but varying by presentation, with Wegovy 2.4 mg pens set at $385.63. Recheck what you pay each January.

Sources

1. First GLP-1 pill for obesity from Novo Nordisk launches in the U.S. — CNBC
2. Wegovy-maker Novo Nordisk warns ‘unprecedented’ price pressure to hit sales — Reuters
3. President Trump Launches TrumpRx.gov — The White House
4. Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic, and Rybelsus — PR Newswire
5. Warning Letter: Novo Nordisk Inc. MARCS-CMS 717576 — FDA
6. Novo, Hims reach deal to sell GLP-1 drugs together — BioPharma Dive
7. FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide — FDA
8. FDA approves Lilly’s Foundayo (orforglipron) — Eli Lilly and Company
9. Medicare GLP-1 Bridge — CMS
10. Wegovy pill prescriptions surpass 3 million — PR Newswire
11. India is launching cheap weight-loss drugs — but Novo Nordisk may not lose out — CNBC
12. Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial — Eli Lilly and Company
13. Novo Nordisk wins EU approval for Wegovy weight-loss pill — Reuters
14. Novo Nordisk says semaglutide cut obesity rates in young children in trial — Reuters
15. Novo Nordisk Form 6-K: REDEFINE 4 headline results — U.S. Securities and Exchange Commission
16. Novo Nordisk Form 6-K: 2026 sales and operating profit outlook, 3 February 2026 — U.S. Securities and Exchange Commission
17. More children under 12 in US are being prescribed weight-loss drugs, study finds — Reuters